EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003

Vinai Gondi iD, Stephanie L Pugh, Minesh P Mehta iD, Jeffrey S Wefel iD, Wolfgang A Tomé iD, Alexander Y Sun, John Grecula, Kristin J Redmond iD, Shannon Fogh, Laurie Gaspar, Andre Konski, Joseph Bovi iD und 20 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-25-00221 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Vinai Gondi und 31 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine, Chicago, IL. Hauptthemen laut MEDLINE: Cranial Irradiation, Lung Neoplasms, Small Cell Lung Carcinoma, Brain Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Hippocampal avoidance (HA) during therapeutic whole-brain radiotherapy reduces the risk of neurocognitive function (NCF) toxicity in patients with brain metastasis. This trial hypothesized that HA during prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) leads to noninferior intracranial relapse (ICR) and reduction in NCF toxicity. METHODS This randomized phase II/III trial enrolled patients with SCLC, no brain metastases, and response to chemotherapy. The primary end points were 12-month ICR (noninferiority design, randomized phase II) and 6-month Hopkins Verbal Learning Test–Revised (HVLT-R) Delayed Recall (DR) failure (phase III). Secondary end points were failure in any NCF test, health-related quality of life (HRQOL), overall survival (OS), and toxicity. RESULTS From December 2015 to June 2022, 393 patients were randomly assigned. The median age was 64 years. Stage and memantine usage were balanced. The median follow-up was 17.0 months (all patients) and 30.8 months (alive patients). HA-PCI had noninferior 12-month ICR rate (PCI 14.8% v HA-PCI 14.7%, P < .0001). Six-month HVLT-R DR deterioration was not significantly different (PCI 30.0% v HA-PCI 25.5%, P = .28). Addition of HA to PCI reduced the risk of failure in any NCF test (adjusted hazard ratio [HR], 0.78; 95% CI [0.61 to 0.99]; P = .039). Addition of HA to PCI was not associated with longitudinal change in any HRQOL domain. There were no differences in OS (adjusted HR, 0.88 [95% CI, 0.67 to 1.14]; P = .33) or grade ≥3 toxicity (PCI 31.4% v HA-PCI 30.7%, P = .88). CONCLUSION Although the study did not meet its primary end point of DR preservation, HA during PCI reduces the risk of overall neurocognitive toxicity with noninferior ICR risk and similar survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cranial IrradiationLung NeoplasmsSmall Cell Lung CarcinomaBrain NeoplasmsHippocampusHumansFemaleMaleMiddle AgedAgedQuality of LifeAdult

Autor:innen und Institutionen

  • Northwestern University Feinberg School of Medicine, Chicago, IL.
  • NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
  • American College of Radiology, Philadelphia, PA.
  • Miami Cancer Institute, Miami, FL.
  • University of Texas MD Anderson Cancer Center, Houston, TX.
  • Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.

ORCID-Profile: Vinai Gondi, Minesh P Mehta, Jeffrey S Wefel, Wolfgang A Tomé, Kristin J Redmond, Joseph Bovi, Clifford G Robinson, Benjamin Corn, Gregory M Videtic, Benjamin H Lok, Kiran Devisetty, Vijayananda Kundapur, Abraham J Wu, Edward C McCarron, Andrew M Baschnagel, Rebecca Paulus, Lisa A Kachnic

Förderung

  • NCI NIH HHS

Zitieren

APA

Gondi, V., Pugh, S. L., Mehta, M. P., Wefel, J. S., Tomé, W. A., Sun, A. Y., Grecula, J., Redmond, K. J., Fogh, S., Gaspar, L., Konski, A., Bovi, J., Robinson, C. G., Corn, B., Videtic, G. M., Lok, B. H., Yoon, H. A., Heinzerling, J. H., DeNittis, A. S., …, & NRG Oncology (2025). Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00221

Vancouver

Gondi V, Pugh SL, Mehta MP, Wefel JS, Tomé WA, Sun AY, et al. Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00221

BibTeX
@article{Gondi2025,
  author = {Gondi, Vinai and Pugh, Stephanie L and Mehta, Minesh P and Wefel, Jeffrey S and Tomé, Wolfgang A and Sun, Alexander Y and Grecula, John and Redmond, Kristin J and Fogh, Shannon and Gaspar, Laurie and Konski, Andre and Bovi, Joseph and Robinson, Clifford G and Corn, Benjamin and Videtic, Gregory M and Lok, Benjamin H and Yoon, Harold A and Heinzerling, John H and DeNittis, Albert S and McGarry, Ronald C and Devisetty, Kiran and Kundapur, Vijayananda and Wu, Abraham J and McCarron, Edward C and Thibault, Isabelle and Simon, Edmund L and Baschnagel, Andrew M and Narayan, Samir and Pollock, Jondavid and Paulus, Rebecca and Kachnic, Lisa A and NRG Oncology, NRG Oncology},
  title = {Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-25-00221}
}
Kostenlos starten →